Karen Lewis - Jan 29, 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Signature
/s/ David Watson, attorney-in-fact for Karen Lewis
Stock symbol
APLS
Transactions as of
Jan 29, 2024
Transactions value $
-$81,402
Form type
4
Date filed
1/31/2024, 04:28 PM
Previous filing
Jan 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale -$23.5K -367 -0.77% $64.14 47.3K Jan 29, 2024 Direct F1
transaction APLS Common Stock Sale -$57.9K -883 -1.87% $65.53 46.4K Jan 30, 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/26/2024.
F2 This is a scheduled sale from an established 10b5-1 plan.